Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...
The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices ...